Carvedilol May Help Childhood Cancer Survivors Avoid Later Heart Failure
2024-01-12
上市批准临床3期
FRIDAY, Jan. 12, 2024 -- Childhood cancer survivors are at increased risk of developing heart failure later in life, due to the chemotherapy that was used to save their lives.
But an already approved drug might help reduce that risk, according to a new report published Jan. 9 in The Lancet Oncology journal.
A blood vessel-relaxing medication called carvedilol is safe for childhood cancer survivors to take and shows promise in reducing the effects of heart injury caused by chemo.
“The growing number of childhood cancer survivors makes the development of early interventions imperative,” said researcher Dr. Saro Armenian, chair of pediatrics at City of Hope Children’s Cancer Center in Los Angeles.
The trial focused on a devastating long-term side effect from a class of chemo called anthracyclines -- increased risk of heart failure, in which the heart becomes too weak to pump enough blood to meet the body’s needs.
The chemo’s damage takes effect gradually over time, as the heart muscle thins and the heart’s chambers enlarge.
Unfortunately, the downward cascade is irreversible after heart function starts to decline, making it urgent that means are found to protect childhood cancer survivors before trouble starts.
Carvedilol is a beta blocker used to treat high blood pressure and heart failure. The U.S. Food and Drug Administration approved the drug in 1995, and it is now available as a generic.
The trial involved 182 childhood cancer survivors across the United States and Canada who took relatively low doses of carvedilol or a placebo for two years.
The clinical trial did not achieve its goal of decreasing the thinning of the heart muscle and enlargement of the chambers, results show.
However, there were significant improvements in the wall stress of the heart’s left lower chamber, or ventricle, researchers said. This is an earlier biomarker of worsening heart health.
Additionally, more patients on placebo developed clinically significant decline in heart function than those on carvedilol -- six versus two, Armenian said.
“The greatest benefit was seen in participants who were very long-term survivors, as well as in those who were highly adherent to the study medication,” Armenian said.
Overall, the trial “sets the stage for a Phase 3 clinical trial that may demonstrate a significant benefit for certain patients who are at an especially high risk of irreversible heart function decline after completion of cancer therapy,” Armenian said.
Sources
City of Hope, news release, Jan. 9, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。